Ceuppens et al. evaluated the therapeutic potential of a FAP-targeting single-domain antibody (4AH29) labeled with either 225Ac or 131I in immunocompetent mice bearing a human FAP-expressing lung cancer model [124]. This evidence concerns the gene FAP and lung cancer.